FLUBLOK- influenza vaccine injection, solution ABD - İngilizce - NLM (National Library of Medicine)

flublok- influenza vaccine injection, solution

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/victoria/361/2011 (h3n2) recombinant hemagglutinin antigen (unii: k5313h4vgs) (influenza a virus a/victoria/361/2011 (h3n2) recombinant hemagglutinin antigen - unii:k5313h4vgs), influenza b virus b/wisconsin/1/2010 recombinant hemagglutinin antigen (unii: n9c76986u2) (influenza b virus b/wisco - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 through 49 years of age. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis), to any component of the vaccine (see description [11]).  reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to flublok. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed. the effect of flublok on embryo-fetal and pre-weaning development was evaluated in pregnant rats. animals were administered flublok by intramuscular injection twice prior to gestation and once during the period of organ

FLUBLOK- influenza vaccine injection, solution ABD - İngilizce - NLM (National Library of Medicine)

flublok- influenza vaccine injection, solution

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen (unii: 1iqz1wce3y) (influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen - unii:1iqz1wce3y), influenza b virus b/massachusetts/2/2012 recombinant hemagglutinin antigen (unii: ayr0wzx7jh) (influenza b virus b/massachus - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 through 49 years of age. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis), to any component of the vaccine (see description [11]).  reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to flublok. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed. the effect of flublok on embryo-fetal and pre-weaning development was evaluated in pregnant rats. animals were administered flublok by intramuscular injection twice prior to gestation and once during the period of organ

PRASTERA- prasterone and ibuprofen kit ABD - İngilizce - NLM (National Library of Medicine)

prastera- prasterone and ibuprofen kit

health science funding, llc - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b) - prasterone 200 mg - oral prasterone (200mg per day) in female patients with active systemic lupus erythematosus (sle) has in several blinded, placebo-controlled randomized clinical studies been associated with a reduced risk of auto-immune flare, §§6.2, 14.1.1, a reduced risk of breast cancer and a reduced risk of death from any cause, §§6.4, 14.2. patients with sle may have depressed serum levels of 5-dehydroepiandrosterone sulfate (5-dheas). oral prasterone has been shown to restore sle patients' serum 5-dheas levels. prastera® oral softgels are intended for use in patients for whom medical evaluation shows a depressed serum level of dhea and thus a distinctive need for exogenous dhea. prastera® oral prasterone softgels are intended to be used under medical supervision, for a patient receiving active and ongoing medical supervision, wherein the patient obtains medical care on a recurring basis for, among other things, instructions on the use of this product. prastera® oral prasterone softgels are intended for the dietary m

SPAQ-CO DISP Dispersible Tablets Tanzanya - İngilizce - Tanzania Medicinces & Medical Devices Authority

spaq-co disp dispersible tablets

shanghai fosun pharmaceutical industrial development co., ltd, china - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 500/25

SPAQ-CO Disp Dispersible Tablets 250/12.5/76.5 Tanzanya - İngilizce - Tanzania Medicinces & Medical Devices Authority

spaq-co disp dispersible tablets 250/12.5/76.5

shanghai fosun pharmaceutical industrial development co., ltd, china - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 250/12.5/76.5